In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 20 of 20

TitleConsultationTypeConsultation end date
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Draft guidanceTechnology appraisal guidance
Bepirovirsen for treating chronic hepatitis B ID6608Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA ID6540Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Draft guidanceTechnology appraisal guidance
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]Draft guidanceTechnology appraisal guidance
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]Review proposal consultationTechnology appraisal guidance
Heart failure - sacubitril valsartan [ID822]Review proposal consultationTechnology appraisal guidance
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]Review proposal consultationTechnology appraisal guidance
Tirzepatide for treating type 2 diabetes [ID3938]Review proposal consultationTechnology appraisal guidance
Empagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]Review proposal consultationTechnology appraisal guidance
Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]Review proposal consultationTechnology appraisal guidance
Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]Review proposal consultationTechnology appraisal guidance
Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]Review proposal consultationTechnology appraisal guidance
Canagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Dapagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Draft guidanceTechnology appraisal guidance
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All